The Louis de la Parte Florida Mental Health Institute

Similar documents
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality

Drug Use Evaluation: Low Dose Quetiapine

Exhibit I-1 Performance Measures. Numerator (general description only)

Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives

Evaluation of Florida Medicaid Behavioral Pharmacy Practice by Racial/Ethnic Minorities Across the Lifespan

Impact of Florida s Medicaid Reform on Recipients of Mental Health Services

Pediatric Psychopharmacology

Evaluation of a Medicaid Psychotropic Drug Management Program in Utah

Pharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines

Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia

MODEL PSYCHOPHARMACOLOGY CURRICULUM

Rexulti (brexpiprazole)

See Important Reminder at the end of this policy for important regulatory and legal information.

Trends in the Prescribing of Psychotropic Medications to Preschoolers Original Contribution

Executive Summary. Classes Under Review: Analysis:

Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care. Illinois Department of Children and Family Services

Introducing ValueOptions Clinical Care Alerts

Understanding the Challenges of Managing Mental Health in the Workplace With a Focus on ADHD

Application of EventFlow to Model the Complexity and Continuity of Antipsychotic Use Among Youth

475 Child & Adolescent Psychopharmacology p.1

Evaluation of Medicaid-Funded Out-of-Home Alternatives for FY 05-06

See Important Reminder at the end of this policy for important regulatory and legal information.

Estimate of the Net Cost of A Prior Authorization Requirement for Certain Mental Health Medications. Prepared by. Driscoll & Fleeter.

Prescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director

Increasing Use of Psychotropics

MEDICAL ASSISTANCE BULLETIN

Table of Contents. 1.0 Policy Statement...1

CY 2017 MMA Performance Measure Scores HEDIS, Core Set, and Agency-defined measures

Psychiatric Care. Course Goals

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

It is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:

MEDICAL POLICY: Telehealth Services

Integrating INTERACT into Interim Pharmacist Reviews

Mental Health & Your Teen Tools, Strategies & Resources

CELEXA (CITALOPRAM) UTILIZATION AND DOSING MANAGEMENT

Antipsychotic Medications Age and Step Therapy

METHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC

GOALS FOR THE PSCYHIATRY CLERKSHIP

Research Journal of Pharmaceutical, Biological and Chemical Sciences

See Important Reminder at the end of this policy for important regulatory and legal information.

Policy Evaluation: Low Dose Quetiapine Safety Edit

Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

Curbing the High Rates of Psychotropic Medication Prescriptions among Children and Youth in Foster Care

Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications

The National Mental Health Association

CHCS. Session Overview 3/7/2014

Community Services - Eligibility

Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults

Outpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years

PRESCRIBING GUIDELINES

v1.4 Reformatted (content numbered) 28/06/12 v1.3 Updated with content identified during Stage 1 blueprinting 23/04/12

Stimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information

Brief Notes on the Mental Health of Children and Adolescents

Clinical Policy: Atomoxetine (Strattera) Reference Number: CP.PST.17 Effective Date:

H. R To prohibit the use of Federal funds for any universal or mandatory mental health screening program. IN THE HOUSE OF REPRESENTATIVES

Idaho DUR Board Meeting Minutes

Goal: To learn about and evaluate the value of various biologically-based methods in the treatment of different forms of psychopathology

See Important Reminder at the end of this policy for important regulatory and legal information.

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

Idaho DUR Board Meeting Minutes

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.

See Important Reminder at the end of this policy for important regulatory and legal information.

Geodon for anxiety and depression

European Network for Hyperkinetic Disorders EUNETHYDIS

Impact of Psychotropics in School

Best Practices in Prescribing Benzodiazepines. Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center

Screening, Brief Intervention, and Referral to Treatment (SBIRT): Mental Disorders

Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: CP.PMN.121 Effective Date: Last Review Date: Line of Business: Medicaid

Major Depressive Disorder (MDD) in Children under Age 6

See Important Reminder at the end of this policy for important regulatory and legal information.

Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009

BY-STATE MENTAL HEALTH SERVICES AND EXPENDITURES IN MEDICAID, 1999

Understanding the Challenges of Managing Mental Health in the Workplace With a Focus on ADHD

Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: NH.PMN.36 Effective Date: Last Review Date: Line of Business: Medicaid

Bipolar Disorder Or Drugs True Stories Of Life In A Psychiatric Hospital Book 5

EXAMINING CHILDREN S BEHAVIORAL HEALTH SERVICE USE AND EXPENDITURES,

CYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID

Psychotropic Medication for Dependent Children

Children s TiPS. Children s Telephonic Psychiatric Consultation Service. General Orientation Materials Abigail Schlesinger, MD

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

NorthSTAR. Pharmacy Manual

Citation for published version (APA): Faber, A. (2006). Stimulant treatment in children: A Dutch perspective. s.n.

The Maudsley Prescribing Guidelines in

Printing: Psychiatric Drugging of Infants and Toddlers in the US - Part I

Child and Adolescent Psychiatry Trends. ADAMHS Board - 28 Oct 2014

Asperger s Syndrome. severe difficulties interacting socially (Gillberg 2002). He named this difficulty

Clinical Policy: Olanzapine Orally Disintegrating Tablet (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: Last Review Date: 02.

Behavioral Health. Behavioral Health. Prescribing Guidelines

Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: CP.PMN.121 Effective Date: Last Review Date: Line of Business: Medicaid

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

Research Protocol for REAP Bipolar Disorder (REAP-BD)

Schizophrenia, a devastating chronic. Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program

For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013

OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS

Manual of Clinical Psychopharmacology

Adult Mental Health Services applicable to Members in the State of Connecticut subject to state law SB1160

Prevalence of Comorbidity and Pattern Drug Use among Children with Attention-deficit hyperactivity disorder: A Single Center in Thailand

Children On Psychotropic Medications

Transcription:

Data Brief December 2003 Mary Rose Murrin, M.A. Kelley Dhont, M.S. David Thornton, M.A. The Louis de la Parte Florida Mental Health Institute Children s Psychotropic Medication Use by Age and Diagnostic Sub-groups Background The Policy and Services Research Data Center Data Brief #2 (October, 2003) examined the diagnostic sub-groups of children receiving Medicaid-funded Mental Health services. That brief indicated that more than 120,000 children statewide received such services from July 1, 2001- June 30, 2002. This report examines the types of psychotropic medications paid for by Medicaid among these diagnostic groups. Practice parameters published by the American Academy of Child and Adolescent Psychiatry (http://www.aacap.org/clinical/parameters/index.htm) indicate that various psychotropic medications may be effective in treating child and adolescent disorders such as ADHD, Anxiety Disorders, Affective Disorders (Bipolar Disorder, Major Depressive Disorder), and Schizophrenia. Only stimulants, Tricyclic antidepressants (TCA), and SSRI antidepressants have been extensively studied for use by children and adolescents. Stimulants have been shown to be effective in short-term treatment for ADHD. Other treatment guidelines are largely based on practice guidelines developed for adults. Predominant medications reviewed in these articles are summarized in Appendix A. Disorders in Appendix A are specified where there is some evidence of treatment effectiveness within a broad therapeutic class, based on articles posted on above website. Policy and Services Research Data Center Mental Health Law & Policy Louis de la Parte Florida Mental Health Institute University of South Florida 13301 Bruce B. Downs Blvd. Tampa, Florida 33612 Methods All claims for Medicaid enrollees from the Florida AHCA Fee-for-service (FFS) Medicaid services data set with dates of service from July 1, 2001 - June 30, 2002 were used in these analyses. Claims were restricted to those submitted for Medicaid enrolled children, ages 1 to 17. All of these claims were included unless they were submitted while the child was enrolled in an HMO or the Pre-paid Mental Health program. Children s Psychotropic Medication Use by Age and Diagnostic Sub-groups December 2003 Louis de la Parte Florida Mental Health Institute 1

The classification scheme developed for Data Brief #2 was used as a basis for this analysis. In addition to the population differences noted above, the following criteria were also employed to ensure diagnostic homogeneity: a) there had to be two primary diagnosis claims within a diagnostic classification group during the year, and b) people with multiple diagnoses were placed in a multiple diagnosis group. The psychotropic medications included in this data brief were brand name medications and their generic equivalents as listed on AHCA s preferred drug list: http://www.fdhc.state.fl.us/medicaid/prescribed_drug/pharm_thera/fmpdl. shtml). * See Appendix A for list of Drugs within Drug Class Results The number of children receiving mental health services reimbursed by Medicaid in Florida within these stricter diagnostic criteria in 2001-2002 was 73,403. The breakdown of children who received mental health services in these diagnostic categories is shown in Table 1. Based on the low N, the Personality Disorder group was re-assigned to the Other Mental Health Disorder group. Table 1. Percentage of Children in Each Diagnostic Group (N=73,403) Diagnostic Group Percentage Developmental/Mental Retardation 25% ADD/ADHD 21% Adjustment Disorder 10% Conduct Disorder 10% Anxiety Disorder 6% Affective Disorder 3 % Personality Disorder 0% Substance Abuse Disorder 1% Schizophrenia/Psychosis 0.4% Other Mental Health Disorders 3% Multiple Diagnoses 21% Children s Psychotropic Medication Use by Age and Diagnostic Sub-groups December 2003 Louis de la Parte Florida Mental Health Institute 2

In Figure 1, it can be seen that the majority of children in four of the diagnostic groups were treated with psychotropic medication during the year. Figure 1. Percentage of Children that Received Any Psychotropic Medication Within Each Diagnostic Group Figure 2 depicts the relative frequency of the types of psychotropic medication prescribed. Figure 2. Percentage of Children in Diagnostic Groups (N=74,186) that Received Psychotropic Medication by Pharmaceutical Type The most commonly prescribed pharmaceutical class was anti-hyperkinetic medication (such as Ritalin or Adderall), followed by atypical anti-psychotic medication, SSRI and newer anti-depressants, and mood stabilizers. As would be expected from treatment parameters in Appendix A, the medications prescribed most often are consistent with the diagnostic groups that most commonly utilize psychotropic medication. However, the percentage of the children using atypical Children s Psychotropic Medication Use by Age and Diagnostic Sub-groups December 2003 Louis de la Parte Florida Mental Health Institute 3

antipsychotics, SSRI or newer antidepressants, and mood stabilizers far exceed the percentage of children in the Schizophrenia and Affective Disorders groups as shown in Table 1. To further examine this relationship between diagnostic group and pharmaceutical group, we limited the analysis to only three of the diagnostic groups that showed significant pharmacy use: ADD/ADHD, Affective Disorders, and Schizophrenia/Psychosis. As Affective Disorders covers both Major Depression and Bipolar Disorders, and these have differing pharmaceutical practice parameters, we broke Affective Disorders into these two distinct diagnostic groups. We restricted Multiple Disorders to those children with multiple diagnoses among these four diagnostic groups only, which included slightly more than one third of the children in this study. The number of children in these groups was 28,619 with 77% in the ADD/ADHD group, 8% in the Multiple Diagnosis group, 9% in the Major Depression group, 4% in the Bipolar Disorder group and 2% in the Schizophrenia/ Psychosis group. Use of specific drug classes for each of these five diagnostic groups is shown in Table 2. Table 2. Percentage of Children in Diagnostic Group that Used Four Major Classes of Psychotropic Medication (N=28,317) Anti-hyper-kinesis Atypical anti-psychotic SSRI or Newer Anti-depressant Mood Stabilizer ADD/ADHD 69% 15% 21% 7% Bipolar Disorder 25% 55% 51% 51% Major Depression 12% 24% 55% 12% Multiple Diagnosis 52% 69% 63% 51% Schizophrenia- Psychosis 13% 70% 39% 22% As can be seen in Table 2, most of the ADD/ADHD diagnostic group was receiving anti-hyperkinesis medication and most of the schizophrenia/psychosis diagnosis children were receiving atypical anti-psychotic medication. In both the multiple diagnosis and Bipolar Disorder groups, it was clear that a wide variety of medication types were prescribed. In all groups, it can readily be demonstrated that many children on psychotropic medication received prescriptions for multiple classes of medication over the course of the year examined. Summary Very little research has been conducted on the effects of psychotropic medication on children. In comparing columns in Table 2, it is clear that many children with adult diagnoses are getting multiple types of medication. This multiple-class prescribing pattern could be due to switching between medication classes or to concomitant prescriptions among multiple classes. Further investigation needs to be conducted to explain this pattern and also compare these findings against practice guidelines for children with mental illnesses. Children s Psychotropic Medication Use by Age and Diagnostic Sub-groups December 2003 Louis de la Parte Florida Mental Health Institute 4

In Data Brief #2 (October 2003), it was shown that the diagnostic groups examined in depth for medication use in this study (ADHD, Schizophrenia/ Psychosis and Affective Disorders ), were comprised largely of school age children, although there was some representation across all age groups. Further work also needs to be done to determine the prevalence and patterns of psychotropic medication use in various age groups of children receiving Medicaid mental health services for these diagnostic groups. Children s Psychotropic Medication Use by Age and Diagnostic Sub-groups December 2003 Louis de la Parte Florida Mental Health Institute 5